This review included 11 studies representing a total of 529 patients. The findings include 1) the OS for 2 years varied from 91% - 98% for 5 of the included studies, 2) three of the included studies had favorable outcomes with 2-year PFS ranging from 73% - 94%. Skin reaction, esophagitis and fatigue were found to be the most common grade 1 and grade 2 toxicities. No acute or late grade 4 and higher toxicities/adverse events were observed. The authors concluded that there are data indicating that PBT may to be an effective treatment against mediastinal Hodgkin and non-Hodgkin lymphoma, but well-designed randomized controlled trials are needed to inform about the optimal approach to proton irradiation in HL and NHL.